BTIG Maintains Buy on Humacyte, Lowers Price Target to $2

Benzinga Newsdesk www.benzinga.com Negative 54.1%

Neg 54.1% Neu 0% Pos 0%

BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $3 to $2.

Comments

No comments yet. Be the first!